TAX 2
Alternative Names: AP-01 - Apmonia Therapeutics; AP-02 - Apmonia Therapeutics; TAX-2Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator CNRS; University of Reims
- Developer Apmonia Therapeutics
- Class Antineoplastics; Antithrombotics; Cyclic peptides
- Mechanism of Action Immunostimulants; Interferon gamma stimulants; Platelet aggregation inhibitors; Thrombospondin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Thrombosis
Highest Development Phases
- No development reported Solid tumours; Thrombosis
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Thrombosis in France (IV, Injection)
- 31 May 2024 Pharmacodynamics and pharmacokinetics data from a preclinical study in Solide tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 Apmonia Therapeutics plans a first in human trial for Solid tumours